Last reviewed · How we verify
Pravastatin and paroxetine combined — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pravastatin and paroxetine combined (Pravastatin and paroxetine combined) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pravastatin and paroxetine combined TARGET | Pravastatin and paroxetine combined | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pravastatin and paroxetine combined CI watch — RSS
- Pravastatin and paroxetine combined CI watch — Atom
- Pravastatin and paroxetine combined CI watch — JSON
- Pravastatin and paroxetine combined alone — RSS
Cite this brief
Drug Landscape (2026). Pravastatin and paroxetine combined — Competitive Intelligence Brief. https://druglandscape.com/ci/pravastatin-and-paroxetine-combined. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab